|
USA-IL-CAPECORAL Azienda Directories
|
Azienda News:
- RINVOQ® (upadacitinib) Dosing for Ulcerative Colitis and Crohns Disease
Inform patients that retinal detachment has been reported in clinical trials with RINVOQ Advise patients to immediately inform their healthcare provider if they develop any sudden changes in vision while receiving RINVOQ Dosage Forms and Strengths: RINVOQ is available in 15 mg, 30 mg, and 45 mg extended-release tablets RINVOQ LQ is available
- RINVOQ® (upadacitinib) Dosing and Lab Monitoring
Inform patients that retinal detachment has been reported in clinical trials with RINVOQ Advise patients to immediately inform their healthcare provider if they develop any sudden changes in vision while receiving RINVOQ Dosage Forms and Strengths: RINVOQ is available in 15 mg, 30 mg, and 45 mg extended-release tablets RINVOQ LQ is available
- RINVOQ® (upadacitinib) PRODUCT FACT SHEET
DOSAGE AND ADMINISTRATION1 For RA PsA AS nr-axSpA: The recommended oral dose is 15 mg once daily For AD: For adults <65 years of age and pediatric patients 12 years of age and older weighing at least 40 kg: • Initiate treatment with 15 mg once daily • If an adequate response is not achieved, consider increasing the dosage to 30 mg once daily
- RINVOQ® (upadacitinib) Dosing for Atopic Dermatitis
Inform patients that retinal detachment has been reported in clinical trials with RINVOQ Advise patients to immediately inform their healthcare provider if they develop any sudden changes in vision while receiving RINVOQ Dosage Forms and Strengths: RINVOQ is available in 15 mg, 30 mg, and 45 mg extended-release tablets RINVOQ LQ is available
- RINVOQ® (upadacitinib) Ulcerative Colitis Dosing Guide
The recommended dose of RINVOQ for maintenance treatment is 15 mg once daily 1 A maintenance dose of 30 mg once daily may be considered for patients with refractory, severe, or extensive disease Discontinue RINVOQ if an adequate therapeutic response is not achieved with the 30 mg dose Use the lowest effective dosage needed to maintain response 1
- RINVOQ® (upadacitinib) - Official Healthcare Professional Site
Inform patients that retinal detachment has been reported in clinical trials with RINVOQ Advise patients to immediately inform their healthcare provider if they develop any sudden changes in vision while receiving RINVOQ Dosage Forms and Strengths: RINVOQ is available in 15 mg, 30 mg, and 45 mg extended-release tablets RINVOQ LQ is available
- RINVOQ® (upadacitinib) Dosing for RA, PsA, AS, nr-axSpA, and GCA
Inform patients that retinal detachment has been reported in clinical trials with RINVOQ Advise patients to immediately inform their healthcare provider if they develop any sudden changes in vision while receiving RINVOQ Dosage Forms and Strengths: RINVOQ is available in 15 mg, 30 mg, and 45 mg extended-release tablets RINVOQ LQ is available
- RINVOQ® (upadacitinib) for Ulcerative Colitis
Inform patients that retinal detachment has been reported in clinical trials with RINVOQ Advise patients to immediately inform their healthcare provider if they develop any sudden changes in vision while receiving RINVOQ Dosage Forms and Strengths: RINVOQ is available in 15 mg, 30 mg, and 45 mg extended-release tablets RINVOQ LQ is available
- RINVOQ® (upadacitinib) for Rheumatoid Arthritis
Advise patients to immediately inform their healthcare provider if they develop any sudden changes in vision while receiving RINVOQ Dosage Forms and Strengths: RINVOQ is available in 15 mg, 30 mg, and 45 mg extended-release tablets RINVOQ LQ is available in a 1 mg mL oral solution
- RINVOQ® (upadacitinib) Rheumatology Dosing Guide
The recommended dosage of RINVOQ in RA, PsA, AS, and nr-axSpA is 15 mg once daily Limitations of Use: RINVOQ is not recommended for use in combination with other Janus kinase (JAK) inhibitors, biologic disease-modifying antirheumatic drugs (bDMARDs), or with potent immunosuppressants such as azathioprine and cyclosporine Instruct patients to:
|
|